Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BMS-986165 (TYK2 inhibitor) in Moderate to Severe Ulcerative Colitis
2019-004878-26Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing BMS-986165 with Placebo (2 arms). Primary endpoint: Clinical response at Week 12. Started Aug 2020; status: completed.
02
Drugs
deucravacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-004878-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004878-26.